Claim extract · Listening Library
Mash interviews: ibogaine, noribogaine, and OUD research history
LAST REVIEWED 2026-09-22 · RESEARCHER INTERVIEW · OBSERVATIONAL PRIMARY
Two high-confidence Listening Library interviews with Deborah Mash on research history, noribogaine interest, and addiction-interruption hypotheses. Podcasts are media; pair claims to Mash-authored primary literature and keep FDA-approval myths separate.
Researcher interview
OUD observational history
Noribogaine development
Listening Library sources (outbound)
drug-science-44-deborah-mash— Drug Science Podcast #44, Apple listing episode link. Confidence: high.psychedelics-today-pt448-mash-2023— Psychedelics Today PT448 (2023-10-06) show notes. Confidence: high.
Testable claims extracted (media → primary)
- Claim (media): Ibogaine can transition some opioid- or cocaine-dependent people from dependence toward abstinence in observational settings.
Primary (observational): Mash et al., “Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes,” Frontiers in Pharmacology 2018;9:529. PMID 29922156, DOI 10.3389/fphar.2018.00529. Label: clinical observations — not an RCT proving cure. - Claim (media): Safety / pharmacokinetics complexity and cardiac concerns are central to clinical development.
Primary: Mash et al., “Ibogaine: Complex Pharmacokinetics, Concerns for Safety, and Preliminary Efficacy Measures,” Ann N Y Acad Sci 2000;914:394–401. PMID 11085338, DOI 10.1111/j.1749-6632.2000.tb05213.x. Pair with current QTc desk. - Claim (policy / media): Investigational noribogaine activity equals FDA approval of noribogaine or ibogaine.
Verdict: False — see Noribogaine FDA-approval claim check. - Claim (overclaim): “Ibogaine cures addiction.”
Verdict: Overstated — cure-language check + OUD evidence.
Verdict
Useful research-history media; observational human signals exist; cure / approval language remains overstated or false. Interviews do not replace denominators, controlled trials, or cardiac-risk literacy.